SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-172225
Filing Date
2024-06-28
Accepted
2024-06-28 16:02:00
Documents
13
Period of Report
2024-06-27
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K d822326d8k.htm   iXBRL 8-K 29610
  Complete submission text file 0001193125-24-172225.txt   153155

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ovid-20240627.xsd EX-101.SCH 2848
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ovid-20240627_lab.xml EX-101.LAB 17995
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ovid-20240627_pre.xml EX-101.PRE 11260
16 EXTRACTED XBRL INSTANCE DOCUMENT d822326d8k_htm.xml XML 3633
Mailing Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001
Business Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001 212-776-4381
Ovid Therapeutics Inc. (Filer) CIK: 0001636651 (see all company filings)

IRS No.: 465270895 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38085 | Film No.: 241085487
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)